	US 11,685,766 B2
	14-3-3 targeting peptides for cancer treatment
Laura Hansen, Bellevue, NE (US); Sandor Lovas, Omaha, NE (US); and Nicholas Palermo, Omaha, NE (US)
Assigned to Creighton University, Omaha, NE (US); and Nutech Ventures, Lincoln, NE (US)
Filed by Creighton University, Omaha, NE (US); and The Board of Regents of the University of Nebraska, Lincoln, NE (US)
Filed on May 7, 2021, as Appl. No. 17/314,795.
Application 17/314,795 is a continuation in part of application No. 16/870,253, filed on May 8, 2020, granted, now 11,518,784.
Claims priority of provisional application 62/845,156, filed on May 8, 2019.
Prior Publication US 2021/0277060 A1, Sep. 9, 2021
Int. Cl. C07K 7/06 (2006.01); A61K 38/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 7/06 (2013.01) [A61P 35/00 (2018.01); A61K 38/00 (2013.01)]

5 Claims

1. A peptide composition, the peptide composition having a peptide consisting of the formula: X—R¹—R²—R³—R⁴-Ser-(PO₃²⁻)—R⁵-Pro-R⁶-Arg-Y, wherein

X represents hydrogen, acetyl or propionyl group,

R¹represents an L or D-amino acid residue selected from the group consisting of: Gln, Trp, Tyr, Phe, His,

R²represents an L or D-amino acid residue selected from the group consisting of: Arg, Lys, Orn,

R³represents an L or D-amino acid residue selected from the group consisting of: Gln, Arg, Lys, Orn, Pro, Trp, Tyr, Phe, His,

R⁴represents an L or D-amino acid residue selected from the group consisting of: Asn, Arg, Lys, Orn, Trp, Tyr, Phe, His,

R⁵represents an L or D-amino acid residue selected from the group consisting of: Ala, Trp, Tyr, Phe, His,

R⁶represents an L or D-amino acid residue selected from the group consisting of: Ala, Trp, Tyr, Phe, His, and

Y represents —OH, amide, methylamide, or ethylamide groups.